In vitro inhibition of neutrophil elastase activity by inhaled anti-Pseudomonas antibiotics used in cystic fibrosis patients.

Mediators of Inflammation
Andreas HectorMatthias Griese

Abstract

Inhaled antibiotics are commonly used in the treatment of cystic fibrosis lung disease. A previous study suggested neutrophil elastase activation by colistin in vitro. Here, we investigated direct effects of the commonly used antibiotics colistin and tobramycin on neutrophil elastase activity. Neutrophil elastase was measured spectrophotometrically. The antibiotics colistin and tobramycin were added in different concentrations with or without the addition of albumin. Generally, neutrophil elastase activity was lower in the absence of albumin compared to its presence. Both antibiotics, colistin and tobramycin, had inhibitory effects on neutrophil elastase activity except for high concentrations of colistin when albumin was absent. Our results suggest inhibitory effects of colistin and tobramycin in vitro. There was a clear dependency of neutrophil elastase measurements on the presence of albumin. Clinical studies are needed to investigate potential direct effects of inhaled antibiotics on neutrophil elastase activity in cystic fibrosis airways.

References

Jun 1, 1993·Archives of Disease in Childhood·J M LittlewoodH Cunliffe
Dec 1, 1995·American Journal of Respiratory and Critical Care Medicine·T L BonfieldM Berger
Dec 10, 1999·The Astrophysical Journal·I YamamuraS T Ridgway
Jan 25, 2000·American Journal of Physiology. Cell Physiology·L PaolucciE Rozengurt
Mar 29, 2002·Methods in Molecular Medicine·Jay B HilliardPamela B Davis
Jul 11, 2002·The European Respiratory Journal·A JonesG S Evans
Oct 3, 2002·The European Respiratory Journal·M E HodsonJ R W Govan
Sep 13, 2003·American Journal of Respiratory and Critical Care Medicine·Claudia L OrdoñezMoira L Aitken
Oct 31, 2003·The Journal of Antimicrobial Chemotherapy·Jian LiJohn Turnidge
Aug 30, 2005·American Journal of Respiratory and Critical Care Medicine·Pamela B Davis
Apr 25, 2006·American Journal of Respiratory and Critical Care Medicine·Frank J Accurso
Aug 26, 2006·The Lancet Infectious Diseases·Jian LiDavid L Paterson
Dec 7, 2007·The European Respiratory Journal·A HaegensE F M Wouters
Dec 8, 2007·Nature Medicine·Ian Sabroe, Moira K B Whyte
Aug 12, 2008·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·C R HansenN Høiby
Sep 2, 2008·The European Respiratory Journal·M GrieseD Hartl
Dec 24, 2008·Thorax·D G DowneyJ S Elborn
Apr 18, 2009·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·J S ElbornC Bertram

❮ Previous
Next ❯

Citations

Aug 24, 2013·Pediatric Pulmonology·John K WongUNKNOWN Australian Respiratory Early Surveillance Team for Cystic Fibrosis (AREST CF)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.